Research
Hormonal
Semaglutid is approved in Germany for the treatment of obesity in adults with a BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with weight-related comorbidities.
Practitioners can consider Semaglutid as a treatment option for eligible patients with obesity.
StrongSupportsmedium confidence
Seit Januar 2022 ist Semaglutid in Deutschland zur Therapie der Adipositas bei Erwachsenen mit einem BMI von ≥ 30 kg/m2 oder ≥ 27 kg/m2 und einer gewichtsbedingten Komorbidität zugelassen.
Why this rating
The claim is based on regulatory approval, indicating strong evidence.
Source
Adipositas – eine behandlungsbedürftige chronische Erkrankung
Svenja Meyhöfer et al. · DMW - Deutsche Medizinische Wochenschrift · 2022
otherCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →